Diamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin Post published:March 29, 2022 Post category:Press Release
MindMed Reports Full Year 2021 Financial Results and Business Highlights Post published:March 28, 2022 Post category:Press Release
Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing Footage Emerges from MAPS Trial Post published:March 25, 2022 Post category:Psychedelic Bulletin
Cybin Announces Additional Adelia Milestone Achievement Post published:March 25, 2022 Post category:Press Release
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study Post published:March 24, 2022 Post category:Press Release
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants Post published:March 24, 2022 Post category:Press Release
Psyched Wellness and the National Research Council of Canada Announce Preliminary Data from Studies of Neuroprotective Properties of AME-1 Post published:March 24, 2022 Post category:Press Release
Gilgamesh Announces Clinical Candidates For Two Programs With First In Human Dosing to Begin in Late 2022 Post published:March 24, 2022 Post category:Press Release
Psilera Expands Computational Chemistry Abilities with the Addition of Dr. Daniel N. Santiago Post published:March 24, 2022 Post category:Press Release